Key result
Testosterone replacement therapy shows uncertain cardiovascular safety in hypogonadal men with ASCVD.
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter of debate. Although testosterone deficiency has been linked to a rise in major adverse CV events, most of the studies on testosterone replacement therapy were not designed to assess CV risk and thus excluded men with advanced heart failure or recent history of myocardial infarction or stroke. Besides considering observational, interventional and prospective studies, this review article evaluates the impact of testosterone on atherosclerosis process, including lipoprotein functionality, progression of carotid intima media thickness, inflammation, coagulation and thromboembolism, quantification of plaque volume and vascular calcification. Until adequately powered studies evaluating testosterone effects in hypogonadal men at increased CV risk are available (TRAVERSE trial), clinicians should ponder the use of testosterone in men with atherosclerotic cardiovascular disease and discuss benefit and harms with the patients.
No takes yet. Share an insight, caveat, or question.
Gencer et al. (2021) conducted a review in Low testosterone conditions. Testosterone replacement therapy was evaluated. Testosterone replacement therapy has uncertain cardiovascular safety, requiring clinicians to carefully weigh benefits and harms in hypogonadal men with atherosclerotic cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: